Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Group Program for First Responders
NCT06471959Phase 2Recruiting
- Sponsor
- Empower Research
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of psilocybin in major depressive disorder (MDD), generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD) and 4 more (2 arms), sponsored by Empower Research. Primary endpoints: Target recruitment rate at 6 months, Retention rate at 8 months and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)generalized anxiety disorder (GAD)obsessive compulsive disorder (OCD)post-traumatic stress disorder (PTSD)prolonged grief disorder (PGD)
Beyond the preview
Go deeper on NCT06471959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471959.